Patent · US Active

Single-domain antibodies against CLL1 and constructs thereof

US12097219B2 · kind B2 · utility

1Cited by

71References

21Claims

0Family size

Assignee

Legend Biotech Ireland Limited · IE

Inventors

Wang Zhang · Nanjing, CN
Yunlei LIU · 安丰镇, CN
Xiaojie TU · 安丰镇, CN
Chenyu Shu · 安丰镇, CN
Tailan Zhan · 安丰镇, CN
Yun ZHANG · Lanzhou, CN
An-Cih Tang
Yafeng Zhang · 安丰镇, CN
Shu Wu · Nanjing, CN
Qing Zhang · Short Hills, US

Key dates

Filing date	Sep 10, 2019
Grant date	Sep 24, 2024
Priority date	—
Expiry date	Nov 3, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2510/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided are single-domain antibodies targeting CLL1 and constructs thereof, including chimeric receptors, immune effector cell engagers and immunoconjugates. Further provided are engineered immune effector cells (such as T cells) comprising an anti-CLL1 chimeric receptor and optionally a second chimeric receptor targeting a second antigen or epitope. Pharmaceutical compositions, kits and methods of treating cancer are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.